Five points to remember if FDA issues a Form 483

Becky Hurt

Our regulatory compliance consulting team includes over 80 former regulators and
inspectors who, alongside seasoned industry experts, help clients mitigate compliance
risks, manage remediations, and restore confidence.
Contact info@parexel.com or visit parexel.com/compliance to learn more.

Five points to remember if FDA issues a Form 483

We need faster endpoints for targeted cancer drugs, and there is one

The New Pragmatism: Clinical Trials, Investment and Regulations Post-COVID-19

Five competencies for operational excellence in cell and gene therapy clinical trials

Importance of Diversity, Equity and Inclusion (DE&I) in medical communications

Battling rare disease: personally and professionally

Three ways to improve your chances that insurers will pay for a new CGT

How market exclusivities can affect your development program

Parexel on the pulse

Drug Development for Rare Disease and Oncology During the COVID-19 Pandemic

Virtual meetings are easy, right?

The impact of COVID-19 on clinical trials in rare disease and oncology

Parexel on the Pulse

Hong Kong Exchange: Nurturing China’s Biotech Valley

Crafting a genomics strategy early is key for successful oncology drug development

eBook: Biopharma in the COVID-19 World

NMPA Guidance on the Management of Clinical Trials during the COVID-19 from July 2020

Top 10 Myths About Working with the FDA for an Oncology Drug Approval

GxP On-Site Inspections are Restarting: Preparing for inspections under the “new normal”

FDA Expectations for Responding to Employees in Pharmaceutical Manufacturing Infected with COVID-19

Using risk assessment decision tree models to maintain safety and data validity in clinical trials during COVID-19